Postpartum evaluation of cardiovascular disease risk for women with pregnancies complicated by hypertension by Escouto, Daniele Cristovao et al.
Accepted Manuscript
Postpartum Evaluation of Cardiovascular Disease Risk for Women with Preg-
nancies Complicated by Hypertension
Daniele Cristovao Escouto, Amanda Green, Lesia Kurlak, Kate Walker, Pamela
Loughna, Lucy Chappell, Fiona Broughton Pipkin, Kate Bramham
PII: S2210-7789(18)30031-X
DOI: https://doi.org/10.1016/j.preghy.2018.06.019
Reference: PREGHY 469
To appear in: Pregnancy Hypertension: An International Journal
of Women's Cardiovascular Health
Received Date: 1 February 2018
Revised Date: 8 June 2018
Accepted Date: 29 June 2018
Please cite this article as: Escouto, D.C., Green, A., Kurlak, L., Walker, K., Loughna, P., Chappell, L., Pipkin, F.B.,
Bramham, K., Postpartum Evaluation of Cardiovascular Disease Risk for Women with Pregnancies Complicated
by Hypertension, Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health (2018),
doi: https://doi.org/10.1016/j.preghy.2018.06.019
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
Postpartum Evaluation of Cardiovascular Disease Risk for Women with Pregnancies Complicated by 
Hypertension  
Daniele Cristovao Escouto1,2,*, Amanda Green3,*, Lesia Kurlak3, Kate Walker3, Pamela Loughna3, Lucy 
Chappell 1, Fiona Broughton Pipkin3, Kate Bramham1 
1 King’s College London, London, United Kingdom. 
2Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil. 
3Nottingham University, United Kingdom 
Word count: 3431 
Corresponding author: Kate Bramham 
Address: Department of Renal Medicine, Division of Transplantation Immunology and Mucosal Biology, 
King’s College London, 10 Cutcombe Road, London, SE5 9RJ, United Kingdom. 
Email: kate.bramham@kcl.ac.uk 
 
*Contributed equally to study
  
 
Abstract 
Objectives: Postpartum stratification of cardiovascular risk for women with pregnancies complicated by 
pre-eclampsia is challenging. Our aim was to identify potential clinical and biomarker predictors of 
future cardiovascular risk at six weeks postpartum in women with hypertensive pregnancies.   
Study design: Prospective longitudinal cohort 
Main outcome measures: Ten year- Framingham cardiovascular risk scores were calculated for 477 
women (94 with gestational hypertension, 288 with pre-eclampsia, 30 with superimposed pre-
eclampsia, 51 with chronic hypertension, 14 women with uncomplicated pregnancies). B-type natriuretic 
peptide (BNP), neutrophil gelatinase–associated lipocalin (NGAL) and placental growth factor (PlGF) 
were quantified at six weeks postpartum.  
Results: Framingham cardiovascular risk scores were not higher in women with pregnancies 
complicated by pre-eclampsia than healthy controls, nor were scores higher in women with pre-existing 
chronic hypertension complicated with superimposed pre-eclampsia compared with those without 
superimposed pre-eclampsia.  Women with gestational hypertension had higher risk scores than women 
with pre-eclampsia and healthy controls. Established risk factors of cardiovascular disease including 
diastolic blood pressure and previously diagnosed chronic hypertension were associated with higher 
scores, and African ethnicity, parity and estimated glomerular filtration rate also were independently 
associated with higher Framingham risk scores at six weeks postpartum. PlGF, BNP and NGAL 
concentrations were not associated with Framingham cardiovascular risk scores after adjustment for 
independent variables.  
Conclusions: A history of pre-eclampsia or superimposed pre-eclampsia in most recent pregnancy was 
not associated with elevated Framingham risk score at six weeks postpartum. Established clinical 
predictors may enable risk stratification at six weeks postpartum, which are not enhanced by the 
biomarkers included in this study.   
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Introduction 
Women with a history of hypertension in pregnancy are at increased risk of future cardiovascular 
disease (CVD) events, [1] and National Institute for Health and Clinical Excellence (NICE) and the 
American Heart Association recommend preventative strategies for CVD in these women. [2,3] Given 
that 10% of women have hypertension in pregnancy, implementation of these recommendations may be 
best targeted if improved identification of those at greatest risk was possible.   
 It is undetermined whether the association between pre-eclampsia and CVD is secondary to 
underlying common risk factors, such as dyslipidaemia and obesity, or if pre-eclampsia is an independent 
factor causing vascular damage. Regardless of the aetiology, it is possible that biomarkers of persistent 
inflammation and endothelial dysfunction, detected after pregnancy[4] could be used as predictors of 
future CVD enabling enhanced stratification of those at greatest risk.  
 The Framingham cardiovascular risk scoring system (FCVRS) is used to assess risk of future 
cardiovascular disease. It is an established and validated algorithm which enables inclusion of 
individuals younger than 40 years and was chosen for assessment of risk in this study.[5] Placental 
growth factor (PlGF) is an angiogenic protein which is synthesized by endothelial cells promoting 
angiogenesis and atherosclerotic intimal thickening in non-pregnant individuals.[6] Abnormal 
concentrations of PlGF in women with history of hypertension in pregnancy could be associated with 
endothelial dysfunction and contribute to atherosclerotic plaque formation and increased risk for 
CVD.[7]  B-type natriuretic peptide (BNP) is released with cardiac ventricular strain, and reflects left 
ventricular function.[8] BNP concentrations are observed to be higher at time of diagnosis in women 
with pre-eclampsia compared with normotensive controls,[9] and could be used to identify women with 
ongoing CVD risk. Plasma neutrophil gelatinase–associated lipocalin NGAL is a marker of inflammation, 
which has been demonstrated to be elevated in pregnant women with pre-eclampsia[10] , and in middle-
aged women with chronic hypertension compared to normotensive controls.[11] Postpartum 
concentrations of PlGF, BNP and NGAL and their role in the prediction of future CVD are yet to be 
elucidated.  
  
 The aim of this exploratory study was to assess the relationship between a history of 
hypertension in pregnancy with CVD assessment by FCVRS at six weeks postpartum, and its association 
with demographics, inflammatory and endothelial biomarkers in order to determine the potential for 
this approach for stratification of risk to guide future implementation of prophylactic strategies. 
  
 
Methods 
All women with a history of hypertension in pregnancy and healthy controls were invited to a six-week 
postpartum follow-up visit at the Maternity Unit, Nottingham City Hospital, United Kingdom. Participants 
were recruited from November 2009 to December 2013. Women with previous diagnosis of chronic 
kidney disease, chronic liver disease and cardiovascular disease were excluded. All participants gave 
written informed consent, and the study was approved by Derby Research and Ethics Committee (ref 
10/H0401/75) and Nottingham University Hospitals Research and Development department (ref 
10OB002). Hypertension in pregnancy was classified according to International Society of Study of 
Hypertension in Pregnancy (ISSHP) guidelines.[12]  Demographics, systolic and diastolic blood pressure 
during pregnancy, previous and current body mass index (BMI), pregnancy characteristics, fetal birth 
weight and outcomes were recorded. Birthweights were assessed by customized birthweight percentile 
charts (www.gestation.net/birthweight_centiles/centile_online.htm).[13] Three measurements of blood 
pressure were conducted in the right arm in the supine position by trained healthcare professionals. 
Random zero mercury sphygmomanometers were used and cuff sizes were chosen accordingly to 
participant’s arm circumference. Mean values between second and third measurements were used in the 
analysis. Plasma samples were taken and stored immediately at -80°C. 
Framingham 10-year cardiovascular risk scores were calculated using the following variables: age, HDL 
cholesterol, total cholesterol, systolic blood pressure, use of anti-hypertensive drugs, smoking status and 
diabetes history.[5] Age only adds risk to the model above 30 years in this predicting score.  A 
standardized age of 30 years was imputed for women younger than 30 years. 
Biomarker analysis  
Standard biochemical assays were undertaken according to the procedures of Nottingham University 
Hospitals NHS Trust. Low-density lipoprotein (LDL) cholesterol was calculated by the Friedewald 
formula. Estimated glomerular filtration rate (eGFR) was calculated by the CKD-EPI equation. Serum and 
urinary creatinine were measured through a Beckman AU analyser using the IDMA-traceable kinetic 
  
colour test with Jaffe method to compensate for protein interference.  Coefficient of variations were 1.7% 
for total cholesterol, 7.0% for high-density (HDL) cholesterol, 2.1% for triglycerides, 2.2% for creatinine. 
Total urinary protein was quantified using Beckman AU clinical chemistry analysers using a colorimetric 
test method.  
Quantitative measurements of plasma BNP, NGAL and PlGF concentrations were undertaken without 
awareness of clinical information using a standard commercially available assay (Cardiorenal Triage 
Assay, Alere Inc., San Diego, CA, USA). Plasma samples were available for 107 women, 49 women with 
history of pre-eclampsia, 30 with previous gestational hypertension, 13 women with chronic 
hypertension, 10 that experienced superimposed pre-eclampsia and 5 women with a previous healthy 
pregnancy. The assay uses fluorescently labelled recombinant murine monoclonal antibodies and 
assesses BNP, NGAL and PlGF specifically and quantitatively, in the range of 5 to 5000 pg/ mL, 15 to 
1300 ng/ mL and 12 to 3000 pg/ mL, respectively, in approximately 15 minutes. BNP and PlGF 
concentrations lower than the inferior limit of detection were reported as 5 pg/ mL and 12 pg/ mL, 
respectively. The total precision (coefficient of variation) on plasma controls at concentrations of BNP 78 
pg/ mL, NGAL 98 ng/ mL and PlGF 85 pg/mL are 9.2%, 12.5% and 12.8%, respectively. Test procedures 
and information are based on the manufacturer’s package insert generated before the study. 
Statistical analysis 
Normality of distribution was explored using a Q-Q plot and logarithmic transformations were 
performed when appropriate. Demographic data are presented as medians (interquartile range) or 
frequencies (percentages). Categorical variables were compared with the use of the λ² test. One-way 
analysis of variance (ANOVA) and Kruskal–Wallis were used to test the differences between groups 
normally distributed and non-normally distributed continuous data respectively, with Mann– Whitney 
post hoc pair-wise test was used for further analysis. Pearson correlation coefficients were calculated to 
assess associations between biomarkers and dependent variables, including individual components of 
the Framingham Cardiovascular Risk Score and total score. For multiple hypotheses testing, Bonferroni's 
correction was used. To assess association between independent variables and increasing Framingham 
Cardiovascular Risk Score, multivariable linear regression using backward selection was performed. 
  
Variables associated with a significance level of 0.20 at univariate linear regression were included in the 
model after highly collinear variables were substituted. Variables included in the algorithm for 
calculation of the Framingham Cardiovascular Risk Score were not included in the model. A probability 
value of α 0.05 was determined to be statistically significant. Analysis was conducted with Stata software 
(version 14.0; StataCorp, College Station). 
  
 
Results: 
Four hundred and seventy seven women were studied at a median time of 7.1 weeks (IQR 6.3-8.3) 
after delivery. Participants were classified according to prior hypertension in pregnancy diagnosis: 94 
(20%) women had gestational hypertension, 288 (60%) women had pre-eclampsia, 30 (6%) women had 
chronic hypertension with superimposed pre-eclampsia, 51 (11%) women had chronic hypertension 
without superimposed pre-eclampsia, and 14 (3%) healthy control women with uncomplicated 
pregnancies. Demographic data, medical history and clinical parameters at postpartum visit are 
displayed in table 1 according to hypertension group.  
 There was no difference in maternal age or time after delivery visit between groups.  The majority 
of women were of European white ethnicity in all groups, and there were no significant differences in 
proportion of women of African or Asiatic ethnicities between groups.   
 Median systolic and diastolic blood pressures at study visit were higher in women with previous 
superimposed pre-eclampsia, chronic hypertension, pre-eclampsia and gestational hypertension when 
compared to healthy controls. Systolic and diastolic blood pressure also were higher in women with 
chronic hypertension with and without superimposed pre-eclampsia and in women with gestational 
hypertension when compared to women with pre-eclampsia without pre-existing disease.  
 There were no significant differences between groups in liver enzymes, triglycerides, total 
cholesterol and HDL concentrations (table 2). Serum creatinine concentrations were higher in women 
with prior gestational hypertension, chronic hypertension with and without superimposed pre-
eclampsia than controls or women with pre-eclampsia Protein to creatinine ratio on random urine 
samples (PCR) was comparable between all groups at the postpartum visit. Forty (14%) women with 
pre-eclampsia, three (10%) women with superimposed pre-eclampsia and four (8%) women with 
chronic hypertension had persistent proteinuria at 6 weeks post-partum, but there were no statistical 
significant differences in proportions between groups. 
 Pregnancy outcomes are detailed in table 3. Gestational age at delivery was lower in women with 
superimposed pre-eclampsia compared to healthy controls, women with gestational hypertension, pre-
  
eclampsia and women with chronic hypertension without superimposed pre-eclampsia. Gestational age 
at delivery also was lower in women with pre-eclampsia compared to women with gestational 
hypertension and chronic hypertension without superimposed pre-eclampsia. The proportion of infants 
with birth weight lower than the 3rd customized centile for gestational age was higher in women with 
superimposed pre-eclampsia compared to all of the other groups.  
 
Framingham 10-years cardiovascular risk score (FCVRS) 
Median FCVRS was low in all groups (1.5% (95% confidence intervals 0.9, 2.0) (Figure 1), i.e. 1.5% 
chance of developing cardiovascular disease in the next 10 years).  Women with chronic hypertension 
without superimposed pre-eclampsia had the highest median risk score, 2.8% (2.0, 3.0) compared with 
women with chronic hypertension with superimposed pre-eclampsia (1.7% (1.0, 2.0), and women with 
gestational hypertension (1.6% (1.0, 2.4)) (P<0.001), or women with pre-eclampsia (1.2% (1.0, 2.0)) or 
controls (1.0% (1.0, 1.5)).  Women with chronic hypertension with superimposed pre-eclampsia also had 
higher median risk when compared to women with pre-eclampsia and healthy controls.  Women with 
gestational hypertension had higher median scores than controls and women with pre-eclampsia. Since 
the sample did not present scores higher enough to be stratified into the conventional risk categories of 
FCVRS (<10%: low risk; 10-20%: moderate risk; >20%: high risk), 12 we defined a ≥ 5% risk threshold 
and categorized women to a <5% lower risk category and ≥5% higher risk category. There were 16 
(17%), 34 (12%), four (13%) and eight (16%) women with gestational hypertension, pre-eclampsia and 
chronic hypertensive with and without superimposed pre-eclampsia in the higher risk category for 
FCVRS. None of the healthy control participants had a FCVRS higher than 5%. There was no relationship 
between FCVRS and gestation at delivery for women with pre-eclampsia or the whole cohort. 
 
Evaluation of association between biomarkers and cardiovascular risk.  
There were no significant differences in plasma BNP, NGAL or PlGF concentrations between groups. Due 
to censored values, BNP and PlGF measurements were categorized according to three different 
  
thresholds (table 4): ≤5 pg/ mL, 5.1 – 9.9 pg/ mL and ≥10 pg/ mL for BNP, and ≤12 pg/ mL, 12.1 – 17.9 
pg/ mL and ≥18 pg/ mL for PlGF and there were no significant differences between groups.  
Correlation coefficients found between FCVRS, biomarkers and known cardiovascular risk factors are 
shown in table 4. The FCVRS demonstrated positive correlations with study visit diastolic blood pressure 
(R 0.597, P<0.001), systolic blood pressure at first antenatal visit (R 0.345, P<0.001), diastolic blood 
pressure at first antenatal visit (R 0.366, P<0.001), BMI at first antenatal visit (R 0.2014, P<0.001), BMI 
postpartum (R 0.200, P<0.001), uric acid concentration postpartum (R 0.092, P0.06), triglycerides (R 
0.167, P<0.001) and LDL cholesterol postpartum (R0.139, P0.05). A negative correlation was found 
between FCVRS and eGFR (R -0.255, P<0.001). NGAL, BNP or PlGF concentrations were not correlated 
with any of the known cardiovascular risk factors evaluated.  
 Factors associated with FCVRS by univariate linear regressions are shown in Table 6.  At 
multivariate linear regression analysis, diastolic blood pressure, parity, African ethnicity and eGFR were 
independently associated with FCVRS. None of the biomarkers, single or in combination, contributed to 
the model performance (Table 7). The post hoc analysis indicated a statistical power of 0.80 to detect a 
hypothesized incremental effect size on R-squared of 0.05 at the alpha level of 0.05 after adding each 
biomarker of interest to the final regression. 
  
 
Discussion 
Framingham cardiovascular 10 year risk scores (FCVRS), for future cardiovascular disease, were 
not higher in women at six weeks postpartum if their pregnancy was complicated by pre-eclampsia 
compared with healthy controls, nor were scores higher in women with pre-existing chronic 
hypertension with pregnancies complicated by superimposed pre-eclampsia compared with those 
without superimposed pre-eclampsia.  Established predictors of cardiovascular risk including diastolic 
blood pressure, and previously diagnosed chronic hypertension were associated with higher FCVRS at 
six weeks postpartum. Women with gestational hypertension had higher FCVRS than women with pre-
eclampsia without pre-existing disease and healthy controls. Other risk factors for cardiovascular disease 
in the general population including African ethnicity, parity and reduced renal function also were 
independently associated with higher FCVRS in this postpartum population.  However, endothelial or 
inflammatory biomarkers tested did not contribute to risk stratification by FCVRS. 
Meta-analyses of observational studies have demonstrated a two-fold increase in the risk for CVD 
later in life in women with previous pre-eclampsia compared to those normotensive pregnancies. 
[1,14,15] However, at six week postpartum there were no differences in FCVRS between women 
pregnancies complicated by pre-eclampsia and normotensive women. Other studies have used FCVRS for 
CVD risk stratification in postpartum women with previous hypertensive disorders of pregnancy and 
reported marginally higher risk scores in women with early-onset pre-eclampsia[16] and women with 
previous pre-eclampsia women with persistent hypertension[17] compared to women with 
uncomplicated pregnancies. Increased cardiovascular risk in women with pre-eclampsia is strongly 
associated with severity of disease, including need for preterm delivery, and has been estimated to be 
two-fold higher in those with severe compared with mild disease.[15] The cohort included in the present 
study predominantly had milder presentations of pre-eclampsia and it is possible that the low FCVRS 
risk scores calculated in women with pregnancies complicated by pre-eclampsia in the present study 
reflects a lower risk group.  However, in keeping with our findings, others have recently reported that 
women with gestational hypertension have a greater risk of future cardiovascular disease then women 
  
with pre-eclampsia [18] which might reflect underlying chronic hypertension, particularly in 
multiparous women. 
 Alternatively, the FCVRS model, generated from an older population of men and women (age 30 to 
74 years), may not be directly comparable to a younger female population. Furthermore, age contributes 
significantly to the predicting equation and thus risk scores for CVD in this cohort may be 
underestimated.  Absolute predictive performance of the FCVRS in this population, and the contribution 
of pre-eclampsia severity remains to be confirmed in a longitudinal cohort, and generation of tailored 
algorithms for postpartum women is likely to be needed. 
 Women with chronic hypertension with or without superimposed pre-eclampsia are frequently 
excluded from large prospective studies evaluating cardiovascular events postpartum. However, in a 
recent cohort study reported cardiovascular outcomes over 50 years after pregnancy in over 14,000 
women including those with pre-existing hypertension superimposed pre-eclampsia in women with 
chronic hypertension was associated with a nearly six-fold increase in cardiovascular events, compared 
with a four-fold increase for women with chronic hypertension without superimposed pre-
eclampsia.[19] In contrast, in the present study women with superimposed pre-eclampsia did not have a 
higher FCVRS compared with women with chronic hypertension, which provides further evidence for the 
need for the generation of a specific postpartum cardiovascular risk score as pregnancy complications in 
isolation appear to be insufficient to identify those at risk, although this finding may be limited by small 
numbers in this group. 
Blood pressure and African ethnicity are well-established risk factors for cardiovascular disease 
in the general population,[20] but has not previously been studied in postpartum women, and were also 
identified as independent predictors in this cohort.  The FCVRS does not include ethnicity which is likely 
to reflect the white European population used to develop the algorithm. In the present study, primigravid 
women in the index pregnancy had significantly lower FCVRS than parous women, but it is not clear 
whether this reflects differences in maternal age. However, others also have reported parity to be 
independently associated with increased risk of death from ischaemic heart disease.[21] Similarly the 
negative association of renal function with CVD risk is well recognised in the general population, and 
  
some studies have shown predictive algorithms including eGFR with better performance than the FCVRS 
alone.[23,24] However, the association between eGFR and FCVRS has not previously been described in a 
cohort of postpartum women with hypertensive pregnancy, and requires validation in a larger 
prospective cohort. 
Other established and potentially modifiable risk factors including total cholesterol and LDL were 
not different between women with different hypertensive disorders of pregnancy, in contrast to the 
findings of Verbeek et al who reported a less favourable lipid profile in women with early onset pre-
eclampsia compared to those with late onset or gestational hypertension.[24]  However, the small 
number of women with early onset pre-eclampsia in this cohort prohibited a meaningful comparison 
with later onset disease. 
 Natriuretic peptides including BNP and NT-pro-BNP which are correlated with left ventricular 
function, have been demonstrated to predict mortality due to cardiovascular disease in older 
populations,[8]and several studies have reported raised concentrations of natriuretic peptides at time of 
diagnosis of pre-eclampsia and associations with future cardiovascular complications proposed. [9] 
However, there are conflicting studies of natriuretic peptide concentrations in postpartum studies with 
some reporting elevated NT-pro-BNP concentrations in women with previous pre-eclampsia at three to 
six months postpartum compared to women with non-complicated pregnancies[25] and others reporting 
no difference in BNP concentrations between women with previous pre-eclampsia and healthy controls 
at one to four weeks postpartum.[26,27] Postpartum comparison of BNP concentrations between 
women with pre-eclampsia and pre-existing chronic hypertension has not previously been reported, and 
no differences were identified in this study.  The absence of any association between BNP concentration 
and future CVD risk suggests that this marker is unlikely to have any useful predictive value in clinical 
practice. 
 Women with previous pre-eclampsia are reported to have altered acute inflammatory responses 
at several months to years after delivery,[28] particularly in those with early onset pre-eclampsia,[24] 
which has been proposed to contribute to future cardiovascular disease.  Small studies have described 
elevated plasma and serum NGAL in women with pre-eclampsia compared to healthy controls,[29] and 
  
in older women with hypertension,[11] in keeping with increased inflammation. To our knowledge, 
plasma NGAL concentrations have not been explored in postpartum women. Plasma NGAL 
concentrations were similar in all women with hypertensive disorders of pregnancy and was not 
associated with FCVRS.  This finding is comparable to a report of urinary NGAL concentrations which 
were elevated in pregnant women with severe pre-eclampsia compared with women with chronic 
hypertension and healthy controls but differences had resolved by three to eight weeks postpartum,[30]  
although urinary and plasma concentrations may not be directly comparable. 
Angiogenic imbalance, including elevated or decreased PlGF has been demonstrated to lead to 
endothelial damage in vitro.[6] A case control study from the Nurses’ Health study suggested that 
elevated PlGF concentrations were predictive of coronary heart disease in asymptomatic women more 
than 10 years after testing. The findings remained significant even after adjustment for comorbid 
conditions such as hypertension and dyslipidaemia (RR 2.78; 95% CI 1.2-6.6),[7]  whereas Akhter et al 
observed elevated sFlt-1:PLGF ratios a year after delivery in women with pre-eclampsia compared to 
controls.  Furthermore, high sFlt-1:PLGF ratios were positively associated with carotid artery intima: 
media thickness ratio, a marker or arterial aging.[31]    In the present study more than 60% of 
participants had PlGF concentrations below the detection threshold of 12 pg/ mL, in keeping with the 
findings of other reports of PlGF concentrations between 1-12 months postpartum.[32-34] In this study 
comparable PlGF concentrations were found between women with different hypertensive disorders of 
pregnancy and controls. Conversely, Noori et al found significantly higher serum PlGF concentrations at 
12 weeks postpartum in women with previous pre-eclampsia or gestational hypertension compared with 
women with normotensive pregnancies, [34] which may reflect differences in plasma and serum 
concentrations postpartum. In agreement with our findings, Gaugler-Senden et al reported similar 
concentrations of angiogenic factors, including PlGF in 16 women almost ten years after early onset 
severe pre-eclampsia compared to 20 women with previous uncomplicated pregnancy.[35]  Thus it is 
possible that persistent angiogenic balance after pregnancy does not contribute to future development of 
cardiovascular disease.  
  
 An important limitation of our study may be inadequate power to detect small differences in 
biomarker concentrations, predictive of future risk. However, in order to have clinical utility, the 
predictive value of additional biomarkers would need to be greater than pre-existing demographic risk 
factors, and none of those studied enhanced predictive performance of traditional risk factors. 
 
Conclusion 
Six weeks after delivery is an opportunistic time to assess cardiovascular risk for women with 
hypertensive disorders of pregnancy.  African ethnicity, parity and reduced eGFR were identified to be 
independently associated with higher cardiovascular risk scores, in addition to diastolic blood pressure 
and a diagnosis of chronic hypertension, but biomarkers assessed did not contribute to risk stratification. 
Future prospective cohort studies to refine and validate a modified FCVRS for use in this population 
derived from relevant individual patient data with targeted biomarkers are needed.   
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Table1. Descriptive characteristics of study participants at postpartum visit divided by diagnostic group  
 
Characteristic Gestational 
Hypertension 
n=94 
Pre-
eclampsia 
n=288 
Superimposed Pre-
eclampsia 
n=30 
Chronic 
Hypertension 
n=51 
Controls 
n=14 
P value 
Age, y 30 (26-35) 29.0 (24-33) 29.0 (24-33) 32.0 (28-36) 31.5 (28-
33) 
0.06 
Time postpartum 
visit, wk 
6.92 (6.1-7.7) 7.14 (6.3-8.6) 7.79 (6.9-8.4) ¥ 6.43 (6.0-8.4) #, 
** 
7.36 (6.1-
8.1) 
0.02 
Body Mass Index, 
kg/m2 
29.9 (25.7-34.1) * 28.2 (24.7-
32.6) †, ¥ 
33.1 (27.0-39.3) *, † 30.1 (25.6-34.9) 
†, # 
24.3 (22.6-
26.7) 
<0.001 
Systolic blood 
pressure, mmHg 
124.0 (120-132)* 120.0 (110-
130) †, ɸ 
130.0 (120-140) *, 
§, ¥ 
134.0 (124-144) 
*, §, ɸ 
110.0 
(100-118) 
<0.001 
Diastolic blood 
pressure, mmHg 
80.0 (74-88) * 78.0 (70-82) 
*, ¥ 
84.5 (76-92) *, § 88.0 (82-94) *, §, 
ɸ 
68.0 (58-
74) 
<0.001 
Primiparous ¶ 35 (21) 203 (70) 20 (67) 21 (41) ‡, §, ||, ɸ 11 (79) 0.002 
Ethnicity ¶       
White 85 (90) 237 (82) 27 (90) 45 (88) 11(79) 0.40 
Black 5 (5) 29 (10) 3 (10) 2 (4) 0 (0) 0.37 
Asian 3 (3) 16 (6) 0 0 1 (7) 0.23 
Other 1 (1) † 6 (2) † 0 4 (8) # 2 (14) 0.02 
Other disease       
Smoking ¶ 13 (14) 17 (7) 4 (10) 4 (8) 1 (7) 0.34 
Alcohol use ¶ 32 (34) 60 (21) ¥ 9 (30) 19 (37) 2 (14) 0.02 
  
Pre-gestational DM 
¶ 
0 9 (3) 1 (3) 0 0 0.35 
Anti-hypertensive 
use 
Nil 
 
87 (93) 
 
250 (87) 
 
15 (50) †, §, ɸ 
 
22 (43) *, §, **, ɸ 
 
14 (100) 
 
< 0.001 
1 drug 7(7) 33 (13) 12 (31) 23 (45) 0  
2 drugs 0 0 1 (3) 5 (10) 0  
≥ 3 drugs 0 0 1 (3) 1 (2) 0  
Values are median (IQR) or ¶frequency (percentage). DM indicates diabetes mellitus; GH, gestational hypertension; PE, pre-
eclampsia; SPE, superimposed pre-eclampsia; CHT, chronic hypertension. 
* P<0.001 when compared to control group. 
† P<0.05when compared to control group. 
ɸ P<0.001 when compared to GH group. 
¥ P<0.05 when compared to GH group. 
§ P <0.001 when compared to PE group. 
# P <0.05 when compared to PE group. 
|| P <0.001 when compared to SPE group.  
** P <0.05 when compared to SPE group. 
 
  
 
Table 2. Laboratory parameters of study participants at postpartum visit divided by diagnostic group 
Characteristic 
Gestational 
Hypertension 
n=94 
Pre-
eclampsia 
n=288 
Superimposed Pre-
eclampsia 
n=30 
Chronic 
Hypertension 
n=51 
Controls 
n=14 
P value 
Total cholesterol, 
mmol/L 
5.20 (4.5-5.9) 5.20 (4.7-
5.8) 
5.00 (4.5-5.9) 5.30 (4.8-5.9) 5.60 (5.2-
6.2) 
0.41 
HDL cholesterol, 
mmol/L 
2.04 (1.7-3.0) 2.04 (1.7-
3.0) 
1.88 (1.7-3.6) 1.95 (1.7-3.3) 2.35 (1.6-
3.0) 
0.68 
LDL cholesterol, 
mmol/L 
2.94 (2.0-3.8) 2.68 (1.8-
3.6) 
2.92 (1.8-3.6) 2.54 (1.8-3.5) 2.27 (1.7-
3.8) 
0.49 
Triglycerides, 
mmol/L 
1.50 (0.9-1.9) 1.30 (0.9-
1.9) 
1.65 (1.1-2.2) 1.30 (0.9-1.8) 1.20 (0.8-
1.6) 
0.13 
Alanine 
Transaminase, U/L 
27.0 (18-45) 24.0 (18-39) 24.0 (18-48) 26.0 (16-41) 24.0 (21-
39) 
0.87 
Creatinine, mmol/L 
77.0 (71-85) * 75.0 (68-81) 78.0 (71-86)  78.0,  (71-87)  72.0 (66-
78) 
0.01 
eGFR, 
ml/min/1.73m2 
109 (101-114) 111 (105-
117)  
108  (104-116) 107 , (101-112) 111 (106-
114) 
0.004 
eGFR < 90 
ml/min/1.73m2 ¶ 
4 (4) 6 (2) 2 (7) 5 (10)  0 0.06 
PCR, mg/mmol 7.0 (6-10) 9.0 (7-15) 9.5 (7-17)  8.0 (6-12) 8.0 (6-10) <0.001 
Proteinuria ≥ 30 
mg/dL ¶ 
0 40 (14)  3 (10)  4 (8) 0 <0.001 
Values are median (IQR) or ¶frequency (percentage). HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; 
eGFR, estimated glomerular filtration rate; PCR, urinary protein to creatinine ratio; GH, gestational hypertension; PE, pre-
eclampsia; SPE, superimposed pre-eclampsia; CHT, chronic hypertension. 
 
  
 
 Table 3. Pregnancy outcomes of study participants at postpartum visit divided by diagnostic group 
Characteristic 
Gestational 
Hypertension 
n=94 
Pre-eclampsia 
n=288 
Superimposed Pre-
eclampsia 
n=30 
Chronic 
Hypertension 
n=51 
Controls 
n=14 
P value 
Maternal Outcomes       
Highest systolic blood 
pressure, mmHg 
155.0 (150-164) * 160.0 (150-173) *, ¥ 161.0 (158-173) *, ¥ 159.0 (149-166) 
* 
131.5 (124-
138) 
<0.001 
Highest diastolic 
blood pressure, 
mmHg 
100.0 (93-104) * 100.5 (95-108) * 105.0 (101-112) *, ¥  99.0 (94-106) * 79.0 (74-83) <0.001 
Highest PCR, mg/mmol 18.0 (13-23) 106.0 (53-298) ɸ 69.0 (50-131) ɸ, # 17.0 (13-22) §, || N/A <0.001 
Gestational diabetes ¶ 1 (1) 9 (3) 1 (3) 0 0 0.61 
HELLP syndrome ¶ N/A 5 (2) 3 (10) N/A N/A 0.04 
Mode of delivery ¶       
Vaginal 41 (44) 117 (40) 13 (43) 29 (57) 8 (57) 0.22 
Assisted vaginal 23 (24) 59 (21) 6 (20) 8 (16) 0 0.24 
  
Emergency Caesarean 
section 
10 (11) 57 (20) ¥ 9 (30) ¥ 5 (10) ** 3 (21.5) 0.04 
Elective Caesarean 
section 
20 (21) 55 (19) 2 (7) 9 (17) 2 (21.5) 0.46 
Neonatal Outcomes       
Stillbirth ¶ 0 4 (1.4) 1 (3) 0 0 0.55 
Gestation at delivery, 
wk 
39.8 (39-41) 38.6 (37-40) ¥ 37.7 (34-39) †, ɸ, # 39.0 (38-40) ¥, 
#, ** 
39.3 (39-40) <0.001 
Preterm <37 wk 6 (6) 82 (28) ɸ, † 12 (40) ɸ, † 5 (10) #, ** 0 <0.001 
Preterm <34 wk 0 29 (10) ɸ 6 (20) ɸ 2 (4) ** 0 <0.001 
Birth Weight, g 
3230 (3000-3590) 2975 
(2330-3400) ɸ 
2470  
(2050-3270) ¥ 
3285  
(2860-3600) #, 
** 
3280 
(3130-3410) 
<0.001 
SGA <10th customised 
birth weight centile ¶ 
19 (20) 84 (29) † 13 (43) ¥, † 12 (24)  0 0.01 
SGA <3rd customised 
birth weight centile ¶ 
9 (10) 53 (18) ¥ 11 (37) ɸ, †, # 6 (12) ** 0 0.004 
  
Neonatal unit 
admission ¶ 
6 (6) 51 (18) ¥ 7 (23) ¥ 2 (4) ¥, #, ** 0 0.001 
Values are median (IQR) or ¶frequency (percentage). PCR indicates urinary protein to creatinine ratio; HELLP, haemolysis, elevated liver enzymes 
and low platelets, SGA, small for gestational age; SCBU, special care baby unit; GH, gestational hypertension; PE, pre-eclampsia; SPE, superimposed 
pre-eclampsia; CHT, chronic hypertension; N/A, non-applicable. 
* P<0.001 when compared to control group. 
† P<0.05 when compared to control group. 
ɸ P<0.001 when compared to GH group. 
¥ P<0.05 when compared to GH group. 
§ P <0.001 when compared to PE group. 
# P <0.05 when compared to PE group. 
|| P <0.001 when compared to SPE group. 
** P <0.05 when compared to SPE group. 
 
 
 
 
  
Table 4. Biomarkers levels of study participants at 6-weeks postpartum visit divided by group 
 
 
Gestational 
Hypertension 
Pre-eclampsia Superimposed  
Pre-eclampsia 
Chronic Hypertension Controls 
 
Biomarker n=30 n=49 n=10 n=13 n=5 P value 
NGAL, ng/ mL 35.0 (31-38) 34.5 (28-44) 28.0 (24-47) 33.0 (29-36) 34.0 (27-35) 0.82 
BNP, pg/mL 8.1 (5-12) 6.2 (5-9) 9.0 (5-15) 7.4 (5-11) 9.3 (5-11) 0.45 
BNP categories ¶ 
   ≤ 5 pg/ mL 
 
10 (33.3) 
 
21 (40) 
 
1 (14) 
 
3 (23) 
 
2 (40) 
0.82 
   5.1 – 9.9 pg/ mL 10 (33.3) 19 (37) 3 (43) 5 (38) 1 (20)  
   ≥ 10 pg/ mL  10 (33.3) 12 (23) 3 (43) 5 (38) 2 (40)  
PlGF,pg/mL 12.1 (12-14) 12.0 (12-14) 12.0 (12-13) 12.0 (12-14) 14.4 (12-15) 0.66 
PlGF categories ¶ 
   ≤ 12 pg/ mL 
   12.1-17.9 pg/ mL 
   ≥ 18 pg/ mL 
 
15 (50) 
13 (43) 
2 (7) 
 
34 (65) 
12 (23) 
6 (11) 
 
5 (72) 
1 (14) 
1 (14) 
 
9 (69) 
2 (15.5) 
2 (15.5) 
 
2 (40) 
2 (40) 
1 (20) 
0.42 
  
Values are median (IQR) or ¶frequency (percentage). NGAL indicates neutrophil gelatinase–associated lipocalin; BNP, B-type natriuretic peptide; PlGF, placental growth factor; GH, 
gestational hypertension; PE, pre-eclampsia; SPE, superimposed pre-eclampsia; CHT, chronic hypertension. 
 
 
 
 
Table 5. Spearman’s correlation coefficients for association between demographics or biomarkers with the 10-year Framingham cardiovascular risk 
score at postpartum visit 
Variable Spearman’s R value P value 
Diastolic blood pressure 0.597 <0.001* 
Systolic blood pressure at booking visit for pregnancy 0.345 <0.001* 
Diastolic blood pressure at booking visit for pregnancy 0.366 <0.001* 
Body mass index 0.200 <0.001* 
Body mass index at booking visit for pregnancy 0.214 <0.001* 
Creatinine 0.113 0.02 
eGFR -0.255 <0.001* 
  
Alanine transaminase 0.039 0.42 
Uric acid 0.092 0.06 
Triglycerides 0.167 <0.001 
LDL cholesterol 0.139 0.005 
BNP † 0.214 0.04 
NGAL ‡ 0.162 0.12 
PlGF † -0.038 0.71 
eGFR indicates estimated glomerular filtration rate; LDL, low-density lipoprotein; BNP, brain natriuretic peptide; NGAL, neutrophil gelatinase-associated lipocalin, PlGF, placental 
growth factor. 
* statistical significance after Bonferroni correction. 
Sample variation: † n=96; ‡ n=91; § n=326. 
 
 
 
  
 
Table 6. Univariate and multivariate analysis of risk variables associated with 10-years Framingham cardiovascular risk score at postpartum visit 
Risk Factor 
Univariate  Multivariate 
OR SE 95% CI P OR SE 95% CI < 0.001 
Diastolic blood pressure 1.0005 0.00004 1.0005-1.0006 < 0.001  1.0005 0.00005 1.0004-1.0006 0.004 
Primiparity 0.994 0.001 0.992-0.996 <0.001  0.997 0.001 0.995-0.999 0.001 
African ethnicity* 1.006 0.002 1.002-1.01 0.001  1.007 0.002 1.003-1.01 0.004 
eGFR 0.9998 0.00005 0.9997-0.99993 <0.001  0.9998 0.00005 0.9997-0.9999 0.061 
Family history of IHD 1.004 0.002 1.0005-1.007 0.024  1.003 0.001 0.9999-1.005 < 0.001 
eGFR indicates estimated glomerular filtration rate; IHD, ischemic heart disease.  
* compared to white European ethnicity. 
Adjusted R-squared of model is 0.33, P<0.001 
 
 
 
  
 
Highlights  
 
• At six weeks postpartum Framingham cardiovascular risk scores are not higher in women with 
pregnancies complicated by pre-eclampsia compared with healthy controls, nor in women with 
pregnancies complicated by superimposed pre-eclampsia compared with women with chronic 
hypertension 
• Women with gestational hypertension have higher Framingham cardiovascular risk scores than 
women with pre-eclampsia and healthy controls at six weeks postpartum 
• B-type natriuretic peptide (BNP), neutrophil gelatinase–associated lipocalin (NGAL) and placental 
growth factor (PlGF) concentrations at 6 weeks after delivery are not associated with 
Framingham cardiovascular risk scores  
 
